



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ram PRATAP, et al

Serial No.: 09/316,313

Group No.: 1612

Filed: May 21, 1999

Examiner.: Evelyn Mei Huang

For: METHOD FOR THE TREATMENT OF MALARIA BY THE USE OF
PRIMAQUINE DERIVATIVE N1-(3-ETHYLIDINOTETRAHYDROFURAN-2-ONE) -N
4-(6-METHOXY-8-QUINOLINYL)-1, 4-PENTANEDIAMINE AS
GAMETCCYTOCIDAL AGENT

Attorney Docket No.: U 012254-3

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

AMENDMENT AFTER FINAL

In response to the Official Action of 28 February 2006, please amend the application as follows:

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.
O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: August 28, 2006

Signature

CLIFFORD J. MASS

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.